Moderna Inc. has entered into a new Credit and Guaranty Agreement with Ares Capital Corporation and other lenders, establishing a $1.5 billion credit facility. The agreement includes a $600 million initial term loan and $900 million in delayed draw term loans, with $400 million available until November 2027 and an additional $500 million contingent upon regulatory milestones and available until November 2028. The loans will accrue interest at either a Term SOFR rate plus 5.50% or a base rate plus 4.50%. The facility is secured by assets of Moderna and its U.S., Canadian, U.K., Swiss, and Australian subsidiaries, and includes liquidity covenants and other customary conditions. The term loans mature in November 2030.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-053816), on November 24, 2025, and is solely responsible for the information contained therein.